CN100503608C - 脱氮嘌呤及其用途 - Google Patents

脱氮嘌呤及其用途 Download PDF

Info

Publication number
CN100503608C
CN100503608C CNB038055082A CN03805508A CN100503608C CN 100503608 C CN100503608 C CN 100503608C CN B038055082 A CNB038055082 A CN B038055082A CN 03805508 A CN03805508 A CN 03805508A CN 100503608 C CN100503608 C CN 100503608C
Authority
CN
China
Prior art keywords
alkyl
aryl
group
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038055082A
Other languages
English (en)
Chinese (zh)
Other versions
CN1630657A (zh
Inventor
简·多恩
希瑟·A·戴维斯
布鲁斯·德科斯塔
费边·古索夫斯凯
菱沼家春
江逸民
金子俊彦
菊池广一
小林诚一
安德烈·莱斯卡尔博
李香伊
村本谦三
大井法人
马克·佩桑特
鲍恩斯·M·塞勒特斯凯
副岛本弘
琳达·特伦布莱
姚烨
横滨弘光
赵延
郑万钧
马克·斯皮韦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN1630657A publication Critical patent/CN1630657A/zh
Application granted granted Critical
Publication of CN100503608C publication Critical patent/CN100503608C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB038055082A 2002-01-07 2003-01-07 脱氮嘌呤及其用途 Expired - Fee Related CN100503608C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34659802P 2002-01-07 2002-01-07
US60/346,598 2002-01-07

Publications (2)

Publication Number Publication Date
CN1630657A CN1630657A (zh) 2005-06-22
CN100503608C true CN100503608C (zh) 2009-06-24

Family

ID=23360154

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038055082A Expired - Fee Related CN100503608C (zh) 2002-01-07 2003-01-07 脱氮嘌呤及其用途

Country Status (22)

Country Link
US (4) US7314936B2 (https=)
EP (2) EP1707566A1 (https=)
JP (1) JP4411455B2 (https=)
KR (2) KR100980163B1 (https=)
CN (1) CN100503608C (https=)
AT (1) ATE327236T1 (https=)
AU (2) AU2003235741B8 (https=)
BR (1) BR0306785A (https=)
CA (1) CA2472479C (https=)
CY (1) CY1106138T1 (https=)
DE (2) DE60305446T4 (https=)
DK (1) DK1474425T3 (https=)
ES (1) ES2262996T3 (https=)
IL (3) IL162884A0 (https=)
MX (1) MXPA04006614A (https=)
NO (1) NO329994B1 (https=)
NZ (2) NZ533958A (https=)
PT (1) PT1474425E (https=)
RU (1) RU2380368C2 (https=)
SI (1) SI1474425T1 (https=)
WO (1) WO2003057696A1 (https=)
ZA (1) ZA200406272B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
AU2003235741B8 (en) * 2002-01-07 2009-01-15 Eisai R&D Management Co., Ltd. Deazapurines and uses thereof
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
EP1846404A1 (en) * 2005-02-02 2007-10-24 Eisai R&D Management Co., Ltd. Crystalline 1h-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
AR055669A1 (es) * 2005-10-03 2007-08-29 Astrazeneca Ab Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125315A2 (en) * 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
US8507473B2 (en) * 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
WO2012033149A1 (ja) 2010-09-10 2012-03-15 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体
BR112013021236B1 (pt) * 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
EP2694056B1 (en) 2011-04-01 2019-10-16 AstraZeneca AB Therapeutic treatment
GB201106814D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
EP2733141B1 (en) 2011-07-15 2019-01-09 Shionogi & Co., Ltd. Azabenzimidazole derivative having ampk-activating activity
PH12014500943A1 (en) 2011-11-30 2014-06-30 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
GB201401198D0 (en) * 2014-01-24 2014-03-12 Bial Portela & Ca Sa Process for the syntheis of substituted urea compounds
EP2913330A1 (en) 2014-02-27 2015-09-02 Laboratoire Biodim Condensed derivatives of imidazole useful as pharmaceuticals
CN104974187A (zh) * 2014-04-10 2015-10-14 吉林省博创药业有限公司 菲罗啉类衍生物及其制备方法和应用
ES2907622T3 (es) * 2014-10-06 2022-04-25 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de BTK y usos de estos
FI3562487T3 (fi) * 2016-12-29 2023-12-14 Ji Xing Pharmaceuticals Hong Kong Ltd Metalloentsyymi-inhibiittoriyhdisteitä
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
KR20190043437A (ko) * 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
JP7265554B2 (ja) 2017-11-14 2023-04-26 ブリストル－マイヤーズ スクイブ カンパニー 置換インドール化合物
KR102781141B1 (ko) 2017-12-15 2025-03-13 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 에테르 화합물
JP7304352B2 (ja) 2017-12-19 2023-07-06 ブリストル－マイヤーズ スクイブ カンパニー ６－アザインドール化合物
WO2019126081A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
MX2020005462A (es) * 2017-12-19 2020-09-07 Bristol Myers Squibb Co Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr).
SG11202005733QA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Diazaindole compounds
EP3728218B1 (en) 2017-12-20 2021-12-01 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
CN112955450A (zh) 2018-10-24 2021-06-11 百时美施贵宝公司 经取代的吲哚和吲唑化合物
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3126224A1 (en) 2019-01-08 2020-07-16 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
KR102904576B1 (ko) 2019-05-09 2025-12-24 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
EP4041730A1 (en) 2019-10-01 2022-08-17 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN114829350B (zh) 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5654305A (en) * 1995-04-19 1997-08-05 Abbott Laboratories Indole piperazine platelet activating factor antagonists
WO2000076505A1 (en) * 1999-06-10 2000-12-21 3M Innovative Properties Company Amide substituted imidazoquinolines
WO2001030778A1 (en) * 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891660A (en) * 1974-02-07 1975-06-24 Squibb & Sons Inc Derivatives of 1H-imidazo{8 4,5-c{9 pyridine-7-carboxylic acids and esters
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US4939146A (en) * 1987-01-29 1990-07-03 Kramer Richard S Method for alleviating ischemic-reperfusion injury
DE3702757A1 (de) 1987-01-30 1988-08-11 Hoechst Ag Neue imidazo- und triazolo-thiadiazine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung, sowie einige bei der herstellung der genannten verbindungen gebildete zwischenprodukte
US4999365A (en) * 1987-03-20 1991-03-12 Merrell Dow Pharmaceuticals Inc. Method of reducing reperfusion injury with imidazol-2-thiones
US4877810A (en) * 1988-02-05 1989-10-31 Eastman Kodak Company Protection of heart tissue from reperfusion injury
US5632991A (en) 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
US5002965A (en) * 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
US5298518A (en) 1989-09-29 1994-03-29 Eisai Co., Ltd. Biphenylmethane derivative and pharmacological use
SE8904355D0 (sv) 1989-12-21 1989-12-21 Perstorp Ab Medicament
US5081253A (en) 1989-12-21 1992-01-14 American Home Products Corporation Imidazo(4,5-c)pyridines as antiosteoporotic agents
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
EP0647226B1 (de) 1992-06-22 1997-09-03 Boehringer Ingelheim Kg 9-AMINO-PYRIDAZINO 4',5' : 3,4]PYRROLO- 2,1-a]ISOCHINOLINE UND DEREN VERWENDUNG FÜR DIE HERSTELLUNG VON PHARMAZEUTISCHEN ZUBEREITUNGEN
US5591835A (en) * 1992-06-29 1997-01-07 Glycomed Incorporated Substituted lactose derivatives
US5360794A (en) 1992-08-03 1994-11-01 Medicarb Inc. Disubstituted and deoxy disubstituted derivatives of α-D-mannofuranosides and β-L-gulofuranosides having anti-inflammatory and anti-proliferative activity
GB9313638D0 (en) 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1997019075A1 (en) * 1995-11-22 1997-05-29 Darwin Discovery Limited Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf)
US5981536A (en) 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
JPH10139709A (ja) 1996-11-13 1998-05-26 Chisso Corp フェニルポリハロアルキルエーテル誘導体、これを含む液晶組成物および液晶表示素子
JP3410476B2 (ja) * 1997-04-18 2003-05-26 大鵬薬品工業株式会社 新規なエポキシコハク酸アミド誘導体又はその塩
PL337888A1 (en) 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
CZ299380B6 (cs) 1998-03-27 2008-07-09 Janssen Pharmaceutica N. V. Pyrimidinová sloucenina, použití této slouceniny pro prípravu léciva, farmaceutický prostredek tutoslouceninu obsahující, zpusob prípravy tohoto prostredku a uvedené slouceniny a kombinace a produktuvedenou slouceninu obsahující
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
SI1194425T1 (sl) 1999-06-23 2005-12-31 Sanofi Aventis Deutschland Substituirani benzimidazoli
MXPA02001565A (es) * 1999-08-13 2005-07-14 Vertex Pharma Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas.
CA2300328A1 (en) 1999-09-14 2001-03-14 Cardiogene Gentherap. Systeme Ag Modulating transcription of genes in vascular cells
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
IL150841A0 (en) * 2000-02-09 2003-02-12 Hokuriku Pharmaceutical 1h-imidazopyridine derivatives
US7186683B2 (en) * 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
AU2002308748A1 (en) * 2001-05-16 2002-11-25 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
JP2005517640A (ja) * 2001-12-04 2005-06-16 エフ．ホフマン−ラ　ロシュ　アーゲー 置換２−アミノ−シクロアルカンカルボキサアミドならびにシステインプロテアーゼインヒビターとしてのその使用
AU2003235741B8 (en) * 2002-01-07 2009-01-15 Eisai R&D Management Co., Ltd. Deazapurines and uses thereof
US6861278B2 (en) * 2002-04-11 2005-03-01 Nordson Corporation Method and apparatus for underfilling semiconductor devices
EP1846404A1 (en) * 2005-02-02 2007-10-24 Eisai R&D Management Co., Ltd. Crystalline 1h-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5654305A (en) * 1995-04-19 1997-08-05 Abbott Laboratories Indole piperazine platelet activating factor antagonists
WO2000076505A1 (en) * 1999-06-10 2000-12-21 3M Innovative Properties Company Amide substituted imidazoquinolines
WO2001030778A1 (en) * 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use

Also Published As

Publication number Publication date
DE60305446D1 (de) 2006-06-29
EP1474425B1 (en) 2006-05-24
US20040186127A1 (en) 2004-09-23
KR20100066593A (ko) 2010-06-17
NO20043290D0 (no) 2004-08-06
US7314936B2 (en) 2008-01-01
US20050124649A1 (en) 2005-06-09
US20110105427A1 (en) 2011-05-05
EP1707566A1 (en) 2006-10-04
DE60305446T4 (de) 2009-07-09
NZ555911A (en) 2008-07-31
US20080103137A1 (en) 2008-05-01
NO20043290L (no) 2004-09-22
RU2004124054A (ru) 2005-04-10
IL197484A0 (en) 2009-12-24
PT1474425E (pt) 2006-09-29
ZA200406272B (en) 2006-01-25
ES2262996T3 (es) 2006-12-01
DK1474425T3 (da) 2006-09-25
ATE327236T1 (de) 2006-06-15
RU2380368C2 (ru) 2010-01-27
BR0306785A (pt) 2004-11-09
DE60305446T2 (de) 2007-03-08
US7868002B2 (en) 2011-01-11
AU2003235741A1 (en) 2003-07-24
KR101108722B1 (ko) 2012-02-17
MXPA04006614A (es) 2004-10-04
JP2005524621A (ja) 2005-08-18
JP4411455B2 (ja) 2010-02-10
CA2472479A1 (en) 2003-07-17
CN1630657A (zh) 2005-06-22
AU2003235741B8 (en) 2009-01-15
CA2472479C (en) 2011-10-11
US8691814B2 (en) 2014-04-08
NO329994B1 (no) 2011-02-07
EP1474425A1 (en) 2004-11-10
AU2003235741B2 (en) 2008-12-04
IL191543A0 (en) 2008-11-03
SI1474425T1 (sl) 2006-10-31
AU2009200689A1 (en) 2009-03-12
KR20040077707A (ko) 2004-09-06
EP1474425B9 (en) 2008-07-02
WO2003057696A1 (en) 2003-07-17
IL162884A0 (en) 2005-11-20
NZ533958A (en) 2007-09-28
KR100980163B1 (ko) 2010-09-03
CY1106138T1 (el) 2011-06-08

Similar Documents

Publication Publication Date Title
CN100503608C (zh) 脱氮嘌呤及其用途
CA2787360C (en) Pyrrol0[3,2-c]pyridinyl-4-benzamide compounds and their use as apoptosis signal-regulating kinase 1 inhibitors
CN105814045B (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
CN105814051B (zh) 用作tnf活性调节剂的四氢咪唑并吡啶衍生物
CN101679428A (zh) 用于治疗皮肤疾病的作为磷酸二酯酶抑制剂的三唑并吡啶类
CN101903384A (zh) 作为蛋白激酶Cθ抑制剂的[1H-吡唑并[3,4-B]吡啶-4-基]-苯基或-吡啶-2-基衍生物
IL229377A (en) Urea pyrrolidinyl and thiourea pyrrolidinyl compounds as trka kinase inhibitors
AU2009345802B2 (en) Phenoxymethyl heterocyclic compounds
CN105722840B (zh) 作为PI3K、mTOR抑制剂的稠合喹啉化合物
CN105814044B (zh) 作为tnf活性调节剂的四氢咪唑并吡啶衍生物
TWI391390B (zh) 吡啶并-嘧啶衍生物，其製備及其應用
WO2022214008A1 (zh) 高活性hpk1激酶抑制剂
WO2004063336A2 (en) Uses of deazapurines for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis
CN102869664A (zh) 吡唑并嘧啶类激酶抑制剂
US20240109899A1 (en) Benzofuran compounds as sting agonists
HK1142077A (en) Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: WEI CAI & D MANAGEMENT CO., LTD.

Free format text: FORMER OWNER: EISAI CO., LTD.

Effective date: 20080627

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080627

Address after: Tokyo, Japan

Applicant after: Eisai R. & D. Management Co., Ltd.

Address before: Tokyo, Japan

Applicant before: Eisai co., Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090624

Termination date: 20150107

EXPY Termination of patent right or utility model